Orbit Discovery and Evergreen Discovery plan to collaborate on identifying cell-targeting peptides in order to develop new radiopharmaceuticals.
Under the agreement, Orbit will develop "peptide leads" that are specific to particular tumors; Evergreen will develop the peptides for clinical use, Orbit said.
